Navigation Links
iSonea's AsthmaSense Smartphone App Now Free
Date:9/4/2012

SEVERNA PARK, Md., Sept. 4, 2012 /PRNewswire/ -- Medical technology company iSonea Ltd. (ASX: ISN; OTCQX: ISOAD) today announced that its asthma management smartphone app, AsthmaSense™ v.1.0.1, is  available for free for iPhone, iPad and Android users through September 30.  According to the American Lung Association, more than seven million children suffer from asthma, making it one of the most chronic childhood disorders in the United States.  Asthma is a leading cause of school absenteeism, accounting for more than 14 million lost school days.

(Logo:  http://photos.prnewswire.com/prnh/20120831/NE65948LOGO )

With AsthmaSense, parents and children have the most intelligent asthma management app at their fingertips. Unlike most health apps which act as passive journals, AsthmaSense v.1.0.1 analyzes user symptoms, medication usage and lung function measurements against the National Institute of Health (NIH) asthma guidelines, alerting the user if it senses that their asthma is not well controlled.

With AsthmaSense, users can input their medication, symptoms and peak flow results, and set alerts for medication and lung function testing. In addition to using this information to determine the status of a user's asthma, the AsthmaSense app stores this data, giving the user and their doctor a better picture of their lung health.

"Autumn is a tough time for asthmatics, especially children. By offering AsthmaSense for free through September, we are increasing access to the most intelligent, easy-to-use asthma management app on the market during this troublesome season," said Michael Thomas, CEO of iSonea Ltd. "At iSonea, we are committed to helping asthmatics breathe easier and we are continuing to develop tools to help people control this disease."

AsthmaSense is the first of iSonea's family of asthma management apps. Future iSonea apps will incorporate the Company's proprietary Acoustic Respiratory Monitoring (ARM™) technology and diagnostic algorithms. The company is also developing the AsthmaSense Cloud™ for data sharing and enhanced capabilities for detecting asthma risk based on changes in environmental conditions such as air quality and weather.

AsthmaSense is available for free on the Apple App Store (for iPhone and iPad users), Google Play and Amazon App Stores (for Android users).

To see how one mother uses iSonea's technology to keep her son's asthma under control, please follow this link.

About iSonea LimitediSonea Limited (ASX: ISN; OTCQX: ISOAD) is an emerging medical technology company developing innovative, non-invasive devices and mobile health apps to improve the management of chronic, costly respiratory disorders such as asthma and COPD. By leveraging iSonea's proprietary Acoustic Respiratory Monitoring™ (ARM) technology with its AsthmaSense™ mobile applications, iSonea is turning smartphones into medical devices—enabling anyone, anywhere, at any time to monitor breathing distress symptoms, in order to take action. iSonea's ARM devices have been cleared for use by the U.S. Food and Drug Administration, the Australian TGA and the European Union CE. For more information, please visit www.SoundAsthma.com.Media Inquiries:Mr. Michael ThomasHelen Shik or Courtney OsgoodChief Executive OfficerSchwartz MSL BostoniSonea Limited+1 781-684-0770+1 410-777-525iSonea@schwartzmsl.com mthomas@iSoneaMed.comwww.schwartzmsl.com website: www.iSoneaMed.com  Forward Looking StatementsCertain statements made in this announcement are forward-looking statements.  These forward-looking statements are not historical facts but rather are based on iSonea's current expectations, estimates and projections about the industry in which iSonea operates, and its beliefs and assumptions.  Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," "guidance" and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of iSonea, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements.  iSonea cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of iSonea only as of the date of this release.  The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made.  iSonea will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.


'/>"/>
SOURCE iSonea Limited
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS/pharmacy Mobile App Transforms Smartphones into Digital ExtraCare Cards
2. As Smartphone Usage Expands, Survey Says Nurses and Nursing Students Want Mobile Access to Credible Drug Data
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 ... the  "Global Anesthesia Disposables Market 2016-2020"  report ... ) ,The global anesthesia disposables market ... of 4.03% during the period 2016-2020.  ... threat to patients, safety. Organizations like the ...
(Date:4/27/2016)... April 27, 2016 Global  ... 2.14 billion by 2022, according to a new ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... the efficiency and accuracy delivered by the new ... for novel urinalysis instruments and consumables. For instance, ...
(Date:4/27/2016)... 2016 At the Sachs CEO ... a Phase 2 clinical study of its lead drug ... cochlear implantation (CI) surgery. This large, placebo-controlled, double-blind, phase ... Germany and France . ... the time of surgery. "Despite advances in cochlear implant ...
Breaking Medicine Technology:
(Date:4/28/2016)... Thousand Oaks, CA (PRWEB) , ... April 28, 2016 , ... ... brand is currently number one in Central America and is looking to grow their ... provide marketing for such an exceptional brand as La Sirena Foods and ...
(Date:4/28/2016)... ... April 28, 2016 , ... Head Over Heels Athletic Arts’ gymnast, ... The competition will be held at the University of Montana on April 28-May 1. ... the Mississippi River. , In order to qualify, Varize needed to place top seven ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... open availability of a new CDISC standard, Clinical Trial Registry (CTR) XML. ... This innovative standard will make it possible to build applications that generate ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online plastic surgery ... The forum section was recently revamped and upgraded to allow even more interaction between ... across the country. , According to the senior editor of Cosmetic Town, “We are ...
(Date:4/28/2016)... Beach, FL (PRWEB) , ... April 28, 2016 , ... ... the spring season. Smart pots are frequently used by professional organic farmers and nurseries ... growers to order their supply of fabric pots. Our goal is to offer wholesale ...
Breaking Medicine News(10 mins):